Daily Stock Setups

Beacon Equity issues Trading Outlook for Cannabis Science Inc.

Posted on: Thu, 30 Jul 2009 06:50:00 EDT

Symbols: MYL, WPI, PRX, CPD, CBIS

Are you looking to increase your ETF knowledge?

DALLAS, Jul 30, 2009 (GlobeNewswire via COMTEX) --
WPI | Quote | Chart | News | PowerRating -- BeaconEquity.com announces an investment report featuring healthcare/drug company Cannabis Science Inc. (OTCBB: CBIS | Quote | Chart | News | PowerRating). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

It is available at: http://www.beaconequity.com/i/CBIS

Get our alerts BEFORE the rest of the market.Follow us on Twitter: http://twitter.com/BeaconEquity

Cannabis Science Inc. (CBIS) is an emerging pharmaceutical company focused on the development and commercialization of phytocannabinoid for the treatment of various neuro-muscular disorders; neuropathic pain related to spinal cord injuries; pain related to AIDS/HIV; respiratory pain related to AIDS/HIV, influenza and autoimmune diseases of asthma and cancer; digestive disorders such as Crohn's disease, irritable bowel syndrome and dermatological infections; as well as sleep disorders.

In the report, the analyst notes:

"Regarding the pain relief market, the Company's strength comes from the weakness in the top three over-the-counter drugs acetaminophen (Tylenol) made by Johnson & Johnson, Bayer's acetylsalicylic acid (Asprin) and ibuprofen (Advil) made by Wyeth. In the case of Tylenol, sudden liver failure has happened in many patients affected by the drug.

"Total sales of all pain relief drugs in the United States is expected to reach $40 billion next year, with more than 80% of the market coming from over-the-counter products, according to a March 2003 Nature Reviews Drug Discovery magazine. CBIS has received a lot of attention from investors due to the response to the rapid spread of the H1N1 virus reported by the WHO, which recent elevated its warning to world pandemic level six."

To read the entire report visit: http://www.beaconequity.com/i/CBIS

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Beacon Equity

Beacon Equity Research
         Jeff Bishop
         (469)-252-3505
         press@beaconequity.com

For full details on Mylan Inc (MYL) MYL. Mylan Inc (MYL) has Short Term PowerRatings at TradingMarkets. Details on Mylan Inc (MYL) Short Term PowerRatings is available at This Link.

For full details on Watson Pharmaceuticals (WPI) WPI. Watson Pharmaceuticals (WPI) has Short Term PowerRatings at TradingMarkets. Details on Watson Pharmaceuticals (WPI) Short Term PowerRatings is available at This Link.

For full details on Par Pharmaceutical Co Inc (PRX) PRX. Par Pharmaceutical Co Inc (PRX) has Short Term PowerRatings at TradingMarkets. Details on Par Pharmaceutical Co Inc (PRX) Short Term PowerRatings is available at This Link.

For full details on Caraco Pharm Labs (CPD) CPD. Caraco Pharm Labs (CPD) has Short Term PowerRatings at TradingMarkets. Details on Caraco Pharm Labs (CPD) Short Term PowerRatings is available at This Link.

For full details on (CBIS) CBIS. (CBIS) has Short Term PowerRatings at TradingMarkets. Details on (CBIS) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.